Talis Biomedical Corporation

Equities

TLIS

US87424L2079

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 11:14:58 2024-05-28 am EDT			5-day change	1st Jan Change
9.2 ^USD	+2.22%		+3.95%	+23.49%

May. 08	Talis Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 02	North American Morning Briefing : Stocks Seen -2-	DJ

Talis Biomedical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 10, 2023 at 04:46 pm EDT

Talis Biomedical Corporation reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 0.581 million compared to USD 0.572 million a year ago. Net loss was USD 15.03 million compared to USD 27.01 million a year ago. Basic loss per share from continuing operations was USD 8.27 compared to USD 15.01 a year ago. Diluted loss per share from continuing operations was USD 8.27 compared to USD 15.01 a year ago.
For the six months, revenue was USD 1.8 million compared to USD 3.76 million a year ago. Net loss was USD 32.87 million compared to USD 60.06 million a year ago. Basic loss per share from continuing operations was USD 18.11 compared to USD 33.47 a year ago. Diluted loss per share from continuing operations was USD 18.11 compared to USD 33.47 a year ago.

Latest news about Talis Biomedical Corporation

Talis Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
North American Morning Briefing : Stocks Seen -2-	Apr. 02	DJ
Talis Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
North American Morning Briefing : Stock Futures Muted; Nvidia Slips in Offhours Trading	Nov. 22	DJ
Talis Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Talis Biomedical Announces Exploration of Strategic Alternatives	Nov. 13	CI
Talis Biomedical Corporation Announces Resignation of Melissa Gilliam from its Board of Directors, as Member of Nominating and Corporate Governance Committee and as Member and Co-Chairperson of Science, Technology and Clinical Affairs Committee	23-09-01	CI
BTIG Adjusts Talis Biomedical's Price Target to $5 From $5.25, Keeps Sell Rating	23-08-16	MT
Talis Biomedical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Transcript : Talis Biomedical Corporation, Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Talis Biomedical Corporation Announces Resignation of Andrew A. Lukowiak as President and Chief Scientific Officer	23-08-02	CI
Talis Biomedical Corporation Announces New Data Supporting the Development of Its Planned CT/NG/TV and Vinal Infections Panels	23-07-27	CI
Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors	23-05-23	CI
Talis Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Transcript : Talis Biomedical Corporation, Q1 2023 Earnings Call, May 11, 2023	23-05-11
Talis Biomedical Corporation Appoints Kimberly Popovits as Lead Independent Director	23-05-08	CI
Talis Biomedical Corporation Announces Executive Changes	23-04-11	CI
Earnings Flash (TLIS) TALIS BIOMEDICAL CORPORATION Reports Q4 Revenue $0.3M	23-03-22	MT
North American Morning Briefing : Stock Futures -2-	23-03-21	DJ
Talis Biomedical Corporation Announces Resignation of Felix Baker from the Board of Directors	23-03-10	CI
Talis Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
Earnings Flash (TLIS) TALIS BIOMEDICAL CORPORATION Posts Q3 Revenue $796,000	22-11-03	MT
Talis Biomedical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-02	CI
Transcript : Talis Biomedical Corporation, Q2 2022 Earnings Call, Aug 02, 2022	22-08-02
Earnings Flash (TLIS) TALIS BIOMEDICAL CORPORATION Posts Q2 Revenue $0.6M	22-08-02	MT

Chart Talis Biomedical Corporation

Duration

Period

More charts

Company Profile

Talis Biomedical Corporation is engaged in transforming diagnostic testing by developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions at the point of care. The Company is engaged in developing the Talis One system, a cloud-enabled molecular diagnostic platform. The Talis One system consists of compact instrument, single-use test cartridges and software that is designed to support a central cloud database, which work together and are designed to provide central laboratory levels of accuracy and be operated by an untrained user. It is also focused on developing Talis One assay kits for respiratory infections, and infections related to women's health and sexually transmitted infections (STIs). It is also developing influenza A and influenza B tests to be included as part of a respiratory panel with its COVID-19 assay (Respiratory Panel), as well as exploring adding a respiratory syncytial virus (RSV) test.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
TALIS BIOMEDICAL CORPORATION	+23.49%	16.4M
MODERNA, INC.	+53.52%	63.85B
IQVIA HOLDINGS INC.	-1.95%	41.83B
LONZA GROUP AG	+39.84%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+14.16%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-20.35%	18.69B
BIO-TECHNE CORPORATION	+3.02%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.17%	12.11B
MEDPACE HOLDINGS, INC.	+29.01%	12.07B

Other Biotechnology & Medical Research